Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PrimePro Mesenchymal Stem Cells for COVID-19 Treatment and Prophylaxis
NCT04573270Phase 1Completed
- Sponsor
- Thomas Advanced Medical LLC
- Start
- Apr 2020
- Primary completion
- Aug 2020
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PrimePro in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Thomas Advanced Medical LLC. Primary endpoints: Survival Rates at 30 days and Contraction Rates at 30 days. Started Apr 2020; status: completed.
02
Drugs
PrimePro
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04573270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04573270.